Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 58
Filtrar
3.
Artigo em Inglês | MEDLINE | ID: mdl-32974757

RESUMO

Poor adherence to warfarin treatment is a contributor to poor quality of treatment, which increases the risk of bleeding and thromboembolic events. This study aims to evaluate the impact of adherence to warfarin therapy on anticoagulation quality during 12 weeks of pharmaceutical care and after 1 year of follow-up for patients with atrial fibrillation and with poor TTR. The Arrhythmia Unit of tertiary hospital in Brazil. We included 262 patients with AF and poor quality of anticoagulation therapy with warfarin (TTR < 50%). Pharmacist-driven therapy management was performed for 12 weeks and patients were also evaluated 1 year after the end of the follow-up with a pharmacist. Adherence was classified into high adherence, medium adherence and low adherence. Impact of adherence to warfarin therapy after pharmaceutical care. Of the 262 patients, 160 were high adherence, 71 were medium adherence and 31 were low adherence. No statistically significant difference is found between adherence groups in demographic and clinical variables. The TTR basal means were not different among adherence groups (p = 0.386). However, the means of TTR 12 weeks and TTR 1 year after the end of protocol were statistically different among adherence groups (p < 0.001 and p = 0.002, respectively). When we compared TTR values at different times within the adherence group, we observed that there is a statistical difference between the three TTR means (basal versus 12 weeks versus 1 year after) within the adherence group (p < 0.001). Patients with poor anticoagulation control, who adhered to the treatment with warfarin during the pharmaceutical care had better anticoagulation quality compared to those who did not adhere to the therapy with warfarin.

4.
Front Pharmacol ; 11: 1056, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32765269

RESUMO

Background: Warfarin is the most common oral anticoagulant drug, especially in low-income and emerging countries, because of the high cost of direct oral anticoagulant (DOACs), or when warfarin is the only proven therapy (mechanical prosthetic valve and kidney dysfunction). The quality of warfarin therapy is directly associated with dose management. Evidence shows that pharmaceutical care achieves a better quality of therapy with warfarin. However, there are no studies showing this intervention in a specific patient group with poor quality of anticoagulation in a long period after the end of the follow-up by a pharmacist. Thus, the aim of this study was to evaluate whether the quality of warfarin therapy driven by a pharmacist remains stable in the long term after the end of follow up with a pharmacist, in AF patients with poor quality of anticoagulation. Methods: This is a prospective study, which evaluated about 2,620 patients and selected 262 patients with AF and poor quality of anticoagulation therapy with warfarin (TTR<50% - based on the last three values of international normalized ratio). Pharmacist-driven therapy management was performed up to 12 weeks. Data from patients were evaluated 1 year after the end of the follow-up with pharmacist. Results: Comparison between mean TTR after 12 weeks of pharmaceutical care (54.1%) and mean TTR one year after the end of the pharmaceutical care (56.5%; p=0.081) did not achieve statistical difference, demonstrating that the increment of quality due to intervention of 12 weeks was maintained for 1 year after intervention. Conclusion: The long-term impact of pharmaceutical care was beneficial for patients with AF and poor quality of warfarin anticoagulation. This design might be an important strategy to treat a subgroup of patients without proven effectiveness of warfarin.

5.
J Am Heart Assoc ; 8(15): e012361, 2019 08 06.
Artigo em Inglês | MEDLINE | ID: mdl-31319747

RESUMO

Background Brugada syndrome and long-QT syndrome may account for at least one third of unexplained sudden cardiac deaths. Dental care in patients with cardiac channelopathies is challenging because of the potential risk of life-threatening events. We hypothesized that the use of local dental anesthesia with lidocaine with and without epinephrine is safe and does not result in life-threatening arrhythmias in patients with channelopathies. Methods and Results We performed a randomized, double-blind pilot trial comparing the use of 2% lidocaine without a vasoconstrictor and with 1:100 000 epinephrine in 2 sessions of restorative dental treatment with a washout period of 7 days (crossover trial). Twenty-eight-hour Holter monitoring was performed, and 12-lead electrocardiography, digital sphygmomanometry, and anxiety scale assessments were also conducted at 3 time points. Fifty-six dental procedures were performed in 28 patients (18 women, 10 men) with cardiac channelopathies: 16 (57.1%) had long-QT syndrome, and 12 (42.9%) had Brugada syndrome; 11 (39.3%) of patients had an implantable defibrillator. The mean age was 45.9±15.9 years. The maximum heart rate increased after the use of epinephrine during the anesthesia period from 82.1 to 85.8 beats per minute (P=0.008). In patients with long-QT syndrome, the median corrected QT was higher, from 450.1 to 465.4 ms (P=0.009) at the end of anesthesia in patients in whom epinephrine was used. The other measurements showed no statistically significant differences. No life-threatening arrhythmias occurred during dental treatment. Conclusions The use of local dental anesthesia with lidocaine, regardless of the use of a vasoconstrictor, did not result in life-threatening arrhythmias and appears to be safe in stable patients with cardiac channelopathies. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT03182777.

10.
Front Pharmacol ; 9: 1052, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30298004

RESUMO

Thromboembolic events are associated with high mortality and morbidity indexes. In this context, warfarin is the most widely prescribed oral anticoagulant agent for preventing and treating these events. This medication has a narrow therapeutic range and, consequently, patients usually have difficulty in achieving and maintaining stable target therapeutics. Some studies on the literature about oral anticoagulant management showed that pharmacists could improve the efficiency of anticoagulant therapy. However, the majority of these studies included general patients retrospectively. The aim of this study was to prospectively evaluate a pharmacist's warfarin management in patients with poor quality of anticoagulation therapy (Time in the Therapeutic Range- TTR < 50%). We included 268 patients with atrial fibrillation (AF) and without stable dose of warfarin (TTR < 50%, based on the last three values of International Normalized Ratio-INR). We followed them up for 12 weeks, INR values were evaluated and, when necessary, the dose adjustments were performed. During the first four visits, patient's INR was measured every 7 days. Then, if INR was within the target therapeutic range (INR: 2-3), the patient was asked to return in 30 days. However, if INR was out the therapeutic target, the patient was asked to return in 7 days. Adherence evaluation was measured through questionnaires and by counting the pills taken. Comparison between basal TTR (which was calculated based on the three last INR values before prospective phase) and TTR of 4 weeks (calculated by considering the INR tests from visits 0 to 4, in the prospective phase of the study) and basal TTR and TTR of 12 weeks (calculated based on the INR tests from visits 0 to 12, in the prospective phase of the study) revealed significant statistical differences (0.144 ± 0.010 vs. 0.382 ± 0.016; and 0.144 ± 0.010 vs. 0.543 ± 0.014, p < 0.001, respectively). We also observed that the mean TTR of 1 year before (retrospective phase) was lower than TTR value after 12 weeks of pharmacist-driven treatment (prospective phase) (0.320 ± 0.015; 0.540 ± 0.015, p < 0.001). In conclusion, pharmaceutical care was able to improve TTR values in patients with AF and poor quality of anticoagulation with warfarin.

11.
PLoS One ; 13(5): e0196763, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29723224

RESUMO

AIM: Acute and subacute cardiotoxicity are characterized by prolongation of the corrected QT interval (QTc) and other measures derived from the QTc interval, such as QTc dispersion (QTdc) and transmural dispersion of repolarization (DTpTe). Although anthracyclines prolong the QTc interval, it is unclear whether breast cancer patients who undergo the ACT chemotherapy regimen of anthracycline (doxorubicin: A), cyclophosphamide (C) and taxane (T) may present with QTc, QTdc and DTpTe prolongation. METHODS: Twenty-three consecutive patients with breast cancer were followed prospectively during ACT chemotherapy and were analyzed according to their QT measurements. QTc, QTdc and DTpTe measurements were determined by a 12-lead electrocardiogram (EKG) prior to chemotherapy (baseline), immediately after the first phase of anthracycline and cyclophosphamide (AC) treatment, and immediately after T treatment. Serum troponin and B-type natriuretic peptide (BNP) levels were also measured. RESULTS: Compared to baseline values, the QTc interval was significantly prolonged after the AC phase (439.7 ± 33.2 ms vs. 472.5 ± 36.3 ms, p = 0.001) and after T treatment (439.7 ± 33.2 ms vs. 467.9 ± 42.6 ms, p < 0.001). Troponin levels were elevated after the AC phase (23.0 pg/mL [min-max: 6.0-85.0] vs. 6.0 pg/mL [min-max: 6.0-22.0], p < 0.001) and after T treatment (25.0 pg/mL [min-max: 6.0-80.0] vs. 6.0 pg/mL [min-max: 6.0-22.0], p < 0.001) compared to baseline values. CONCLUSION: In this prospective study of patients with non-metastatic breast cancer who underwent ACT chemotherapy, significant QTc prolongation and an elevation in serum troponin levels were observed.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Neoplasias da Mama/tratamento farmacológico , Ciclofosfamida/efeitos adversos , Eletrocardiografia/efeitos dos fármacos , Sistema de Condução Cardíaco/efeitos dos fármacos , Cardiopatias/induzido quimicamente , Paclitaxel/efeitos adversos , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia , Neoplasias da Mama/sangue , Neoplasias da Mama/fisiopatologia , Cátions/sangue , Ciclofosfamida/administração & dosagem , Ciclofosfamida/farmacologia , Doxorrubicina/administração & dosagem , Doxorrubicina/efeitos adversos , Doxorrubicina/farmacologia , Feminino , Seguimentos , Cardiopatias/sangue , Cardiopatias/fisiopatologia , Humanos , Pessoa de Meia-Idade , Peptídeo Natriurético Encefálico/sangue , Paclitaxel/administração & dosagem , Paclitaxel/farmacologia , Estudos Prospectivos , Troponina I/sangue
13.
J Am Coll Cardiol ; 70(12): 1510-1524, 2017 Sep 19.
Artigo em Inglês | MEDLINE | ID: mdl-28911515

RESUMO

Trypanosoma cruzi (T. cruzi) infection is endemic in Latin America and is becoming a worldwide health burden. It may lead to heterogeneous phenotypes. Early diagnosis of T. cruzi infection is crucial. Several biomarkers have been reported in Chagas heart disease (ChHD), but most are nonspecific for T. cruzi infection. Prognosis of ChHD patients is worse compared with other etiologies, with sudden cardiac death as an important mode of death. Most ChHD patients display diffuse myocarditis with fibrosis and hypertrophy. The remodeling process seems to be associated with etiopathogenic mechanisms and neurohormonal activation. Pharmacological treatment and antiarrhythmic therapy for ChHD is mostly based on results for other etiologies. Heart transplantation is an established, valuable therapeutic option in refractory ChHD. Implantable cardioverter-defibrillators are indicated for prevention of secondary sudden cardiac death. Specific etiological treatments should be revisited and reserved for select patients. Understanding and management of ChHD need improvement, including development of randomized trials.


Assuntos
Cardiomiopatia Chagásica/etiologia , Cardiomiopatia Chagásica/terapia , Arritmias Cardíacas/etiologia , Cardiomiopatia Chagásica/complicações , Cardiomiopatia Chagásica/diagnóstico , Doença Crônica , Insuficiência Cardíaca/etiologia , Humanos , Prognóstico
14.
Arrhythm Electrophysiol Rev ; 6(2): 80-84, 2017 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-28835839

RESUMO

Radiofrequency (RF) catheter ablation is the treatment of choice in patients with accessory pathways (APs) and Wolff-Parkinson-White syndrome. Endocardial catheter ablation has limitations, including the inability to map and ablate intramural or subepicardial APs. Some of these difficulties can be overcome using an epicardial approach performed through the epicardial venous system or by percutaneous catheterisation of the pericardial space. When a suspected left inferior or infero-paraseptal AP is refractory to ablation or no early activation is found at the endocardium, a transvenous approach via the coronary sinus is warranted because such epicardial pathways can be in close proximity to the coronary venous system. Associated congenital abnormalities, such as right atrial appendage, right ventricle diverticulum, coronary sinus diverticulum and absence of coronary sinus ostium, may also hamper a successful outcome. Percutaneous epicardial subxiphoid approach should be considered when endocardial or transvenous mapping and ablation fails. Epicardial mapping may be successful. It can guide and enhance the effectiveness of endocardial ablation. The finding of no epicardial early activation leads to a more persistent new endocardial attempt. When both endocardial and epicardial ablation are unsuccessful, open-chest surgery is the only option to eliminate the AP.

15.
Arq Bras Cardiol ; 108(1): 70-73, 2017 Jan.
Artigo em Português, Inglês | MEDLINE | ID: mdl-28146213

RESUMO

Compound heterozygosity has been described in inherited arrhythmias, and usually associated with a more severe phenotype. Reports of this occurrence in Brugada syndrome patients are still rare. We report a study of genotype-phenotype correlation after the identification of new variants by genetic testing. We describe the case of an affected child with a combination of two different likely pathogenic SCN5A variants, presenting sinus node dysfunction, flutter and atrial fibrillation, prolonged HV interval, spontaneous type 1 Brugada pattern in the prepubescent age and familiar history of sudden death.


Assuntos
Flutter Atrial/genética , Síndrome de Brugada/genética , Mutação , Canal de Sódio Disparado por Voltagem NAV1.5/genética , Flutter Atrial/fisiopatologia , Síndrome de Brugada/fisiopatologia , Pré-Escolar , Eletrocardiografia , Predisposição Genética para Doença , Heterozigoto , Humanos , Masculino , Linhagem , Fenótipo , Índice de Gravidade de Doença
16.
Europace ; 19(2): 250-258, 2017 02 01.
Artigo em Inglês | MEDLINE | ID: mdl-28175286

RESUMO

Aims: Atrial-oesophageal fistula is a serious complication related to ablation of atrial fibrillation. As its occurrence is rare, there is a great lack of information about their mechanisms, incidence, presentations, and treatment. The objective of this manuscript is to present a series of cases of atrial-oesophageal fistula in Brazil, focusing on incidence, clinical presentation, and follow-up. Methods and results: This is a retrospective multicentre registry of atrial-oesophageal fistula cases that occurred in eight Brazilian centres from 2003 to 2015. Ten cases (0.113%) of atrial-oesophageal fistula were reported in 8863 ablation procedures in the period. Most of the subjects were male (70%) with age 59.6 ± 9.3 years. Eight centres were reference units in atrial fibrillation ablation with an experience over than 200 procedures at the time of fistula occurrence. Oesophageal temperature monitoring was performed in eight cases using coated sensors in six. The first atrial-oesophageal fistula clinical manifestation was typically fever (in six patients), with a median onset time of 16.5 (12­43) days after ablation. There was a delay of 7.8 ± 3.3 days between the first manifestation and the diagnosis in five patients. The treatment was surgical in six cases, clinical in three and stenting in one. Seven patients died (70%) and two developed permanent neurological sequelae. Conclusion: Atrial-oesophageal fistula remains a serious complication following AF ablation despite the incorporation of protective measures and increased technical experience of the groups. The high morbidity and mortality despite the treatment indicates the need to develop adequate preventive strategies.


Assuntos
Fibrilação Atrial/cirurgia , Ablação por Cateter/efeitos adversos , Fístula Esofágica/epidemiologia , Traumatismos Cardíacos/epidemiologia , Adulto , Idoso , Fibrilação Atrial/diagnóstico , Fibrilação Atrial/mortalidade , Fibrilação Atrial/fisiopatologia , Brasil/epidemiologia , Ablação por Cateter/mortalidade , Fístula Esofágica/diagnóstico , Fístula Esofágica/mortalidade , Fístula Esofágica/terapia , Esofagoscopia , Feminino , Febre/epidemiologia , Átrios do Coração/lesões , Traumatismos Cardíacos/diagnóstico , Traumatismos Cardíacos/mortalidade , Traumatismos Cardíacos/terapia , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Sistema de Registros , Estudos Retrospectivos , Fatores de Risco , Fatores de Tempo , Tomografia Computadorizada por Raios X , Resultado do Tratamento
17.
Arq. bras. cardiol ; 108(1): 70-73, Jan. 2017. graf
Artigo em Inglês | LILACS | ID: biblio-1038528

RESUMO

Abstract Compound heterozygosity has been described in inherited arrhythmias, and usually associated with a more severe phenotype. Reports of this occurrence in Brugada syndrome patients are still rare. We report a study of genotype-phenotype correlation after the identification of new variants by genetic testing. We describe the case of an affected child with a combination of two different likely pathogenic SCN5A variants, presenting sinus node dysfunction, flutter and atrial fibrillation, prolonged HV interval, spontaneous type 1 Brugada pattern in the prepubescent age and familiar history of sudden death.


Resumo A heterozigose composta é descrita em arritmias hereditárias, geralmente associada a um fenótipo mais grave. Relatos dessa ocorrência em pacientes com síndrome de Brugada ainda são raros. Neste estudo, descrevemos o caso de uma criança com a combinação de duas novas variantes distintas no gene SCN5A, apresentando disfunção do nó sinusal, flutter e fibrilação atrial, intervalo HV prolongado, padrão tipo 1 espontâneo de Brugada na idade pré-puberal e história familiar de morte súbita.


Assuntos
Humanos , Masculino , Pré-Escolar , Flutter Atrial/genética , Síndrome de Brugada/genética , Canal de Sódio Disparado por Voltagem NAV1.5/genética , Mutação , Linhagem , Fenótipo , Flutter Atrial/fisiopatologia , Índice de Gravidade de Doença , Predisposição Genética para Doença , Eletrocardiografia , Síndrome de Brugada/fisiopatologia , Heterozigoto
18.
Int. j. cardiovasc. sci. (Impr.) ; 30(1): f:61-l:69, jan.-fev. 2017. tab
Artigo em Português | LILACS | ID: biblio-833661

RESUMO

Fundamento: Pacientes submetidos à ressincronização cardíaca podem evoluir com padrões de resposta acima do esperado, com normalização dos parâmetros clínicos e ecocardiográficos. Objetivo: Analisar as características clínicas e ecocardiográficas desta população de super-respondedores, comparando-as com os demais pacientes submetidos à terapia de ressincronização cardíaca. Métodos: Estudo de coorte observacional, prospectivo, envolvendo 146 pacientes, consecutivamente submetidos a implantes de ressincronizador cardíaco. Para comparação das variáveis, foram realizados o teste exato de Fisher e o teste de Mann-Whitney. Foram considerados super-respondedores os pacientes com fração de ejeção > 50 % e classe funcional I/II (New York Heart Association) após 6 meses da terapia de ressincronização cardíaca. Resultados: A idade média foi de 64,8 ± 11,1 anos, sendo 69,8% do sexo masculino, com mediana da fração de ejeção de 29%, sendo 71,5% com bloqueio de ramo esquerdo, 12% com bloqueio de ramo direito associado a bloqueios divisionais; 16,3% com marca-passo cardíaco definitivo, 29,3% com miocardiopatia isquêmica, 59,4% com miocardiopatia dilatada e 11,2% com miocardiopatia chagásica. Foram observados 24 (16,4%) superrespondedores, sendo que 13 (8,9%) apresentaram normalização da fração de ejeção, dos diâmetros diastólicos do ventrículo esquerdo e da classe funcional. Quando comparados com os pacientes não super-respondedores, em relação às características pré-implante, os super-respondedores apresentaram-se mais no sexo feminino (58,3% vs. 22,8%; p = 0,002), maior índice de massa corporal (26,8 vs. 25,5; p = 0,013), maior fração de ejeção basal (31,0 vs. 26,9; p = 0,0003) e menores diâmetros diastólicos do ventrículo esquerdo (65,9 mm vs. 72,6 mm; p = 0,0032). Dez pacientes (41,6% dos super-respondedores) com bloqueio de ramo direito e bloqueio divisional evoluíram como super-respondedores, entretanto apenas um paciente com doença de Chagas e apenas na primeira avaliação. Conclusões: Os super-respondedores apresentaram cardiopatia de base menos avançada e sem diferenças em relação ao tipo de distúrbio de condução basal. Pacientes com bloqueio de ramo direito e bloqueio divisional, mas sem cardiopatia chagásica podem também evoluir como super-respondedores


Background: Patients submitted to cardiac resynchronization may develop response patterns that are higher than expected, with normalization of clinical and echocardiographic parameters. Objective: To analyze the clinical and echocardiographic characteristics of this population of super-responders, comparing them with the other patients submitted to cardiac resynchronization therapy. Methods: A prospective, observational cohort study involving 146 patients consecutively submitted to cardiac resynchronization implants. Fisher's exact test and Mann-Whitney test were performed to compare the variables. Patients with ejection fraction > 50% and functional class I/II (New York Heart Association) were considered super-responders after 6 months of cardiac resynchronization therapy. Results: Mean age was 64.8 ± 11.1 years, with 69.8% of males, with a median ejection fraction of 29%, 71.5% with left bundle-branch block, 12% with right bundle-branch block associated with hemiblocks; 16.3% wearing a definitive cardiac pacemaker, 29.3% with ischemic cardiomyopathy, 59.4% with dilated cardiomyopathy, and 11.2% with Chagasic cardiomyopathy. Twenty-four (16.4%) super-responders were observed, and 13 (8.9%) showed normalization of the ejection fraction, left ventricular diastolic diameters and functional class. When compared to the non-super-responder patients, in relation to the pre-implantation characteristics, the super-responders were more often females (58.3% vs. 22.8%, p = .002), had higher body mass index (26.8 vs. 25.5, p = 0.013), higher baseline ejection fraction (31.0 vs. 26.9, p = 0.0003), and lower left ventricular diastolic diameters (65.9 mm vs. 72.6 mm, p = 0.0032). Ten patients (41.6% of super-responders) with right bundle-branch block and hemiblock progressed to super-responders, although there was only one patient with Chagas' disease among them, and only at the first assessment. Conclusions: Super-responders had less advanced heart disease at baseline and no differences regarding the type of conduction disorder at baseline. Patients with right bundle-branch block and hemiblock, but without Chagasic heart disease may also progress as super-responders


Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Terapia de Ressincronização Cardíaca/métodos , Desfibriladores Implantáveis , Ecocardiografia/métodos , Insuficiência Cardíaca/terapia , Disfunção Ventricular Esquerda/terapia , Fatores Etários , Índice de Massa Corporal , Bloqueio de Ramo/complicações , Bloqueio de Ramo/diagnóstico , Eletrocardiografia/métodos , Ventrículos do Coração , Estudos Prospectivos , Fatores Sexuais , Análise Estatística
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...